13F Holdings
中文EN

HUMA Humacyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%

Returns

ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.04M$0———
Cost of revenue$9.70M$0———
Gross profit-$7.66M$0———
R&D expense$69.30M$88.60M$76.55M$63.26M$61.34M
SG&A expense$31.17M$25.80M$23.50M$22.88M$21.13M
Operating income-$108.14M-$114.40M-$100.05M-$84.58M-$81.21M
Interest expense$11.25M$9.28M$6.60M$6.20M$4.35M
Pretax income-$40.83M————
Income tax$0$0$0$0$0
Net income-$40.83M-$148.70M-$110.78M-$11.96M-$26.48M
EBITDA-$102.81M-$109.29M-$94.39M-$78.43M-$75.03M
EPS (basic)-0.26-1.26-1.07-0.12-0.66
EPS (diluted)-0.26-1.26-1.07-0.12-0.66
Weighted avg. shares (diluted)158.16M118.48M103.42M103.05M39.97M
Balance sheet
Cash & equivalents$50.50M$95.29M$80.80M$149.77M$217.50M
Short-term investments——$0$2.11M$8.00M
Receivables$441,000$0$0$31,000$176,000
Inventory$13.59M$0———
Current assets$67.80M$47.86M$83.28M$154.21M$229.34M
PP&E, net$18.54M$23.06M$26.79M$30.04M$35.03M
Total assets$116.37M$137.87M$128.22M$204.30M$286.53M
Current liabilities$18.37M$19.95M$18.44M$19.58M$11.05M
Long-term debt$35.44M$0——$30.00M
Total debt$35.44M$0——$30.00M
Total liabilities$113.26M$190.54M$114.68M$87.37M$164.36M
Shareholders' equity$3.11M-$52.67M$13.55M$116.93M$122.17M
Net debt-$15.05M-$95.29M——-$187.50M
Shares outstanding193.00M130.03M103.67M103.23M103.00M
Cash flow statement
Operating cash flow-$105.04M-$98.12M-$73.31M-$71.13M-$81.19M
Capital expenditure$884,000$1.57M$2.28M$1.05M$220,000
Free cash flow-$105.93M-$99.69M-$75.58M-$72.18M-$81.41M
Investing cash flow-$884,000-$1.57M-$173,000$4.84M-$8.22M
Financing cash flow$61.49M$114.18M$4.51M-$1.45M$266.98M
Depreciation & amortization$5.33M$5.10M$5.66M$6.15M$6.18M
Stock-based compensation$9.75M$6.14M$6.83M$6.18M$10.15M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.